The potential of EGFR inhibitors for inducing anti-tumor immunity offers the feasibility of combining the EGFR-targeting therapies, including TKIs and CAR-T with ICIs in EGFR-overexpressed TNBC [207,208]. Here, EGFR is linked to neoplasm.